Psilocybin Assisted Therapy Market Share

North America Market Analysis 

North America is dominating the psilocybin assisted therapy market and is anticipated to hold the market share of 42.9% at a CAGR of 17.3% by 2034. The market is driven by rising federal funding, regulatory reforms, and clinical acceptance in the U.S. and Canada. Further, the initiatives such as NIIH, Medicare, and Medicaid in the U.S. have increased the access and reimbursement framework to USD 5.4 billion. Over 199,970 patients are supported yearly in Ontario due to provincial financing and Health Canada's Special Access Program, which has up surged the deployment of treatment in Canada. The strategic collaborations, advancements in APIs, and clinical networks make the region as the dominant leader in psilocybin-assisted therapy expansion.

The U.S. psilocybin assisted therapy market is growing due to federal investment, enhanced patient demand, and increased institutional adoption. The CDC and AHRQ together spent USD 5.3 billion in 2023 on psychedelic treatment programs, financing nationwide clinical trials and community mental health centers. Medicaid expenditure totaled USD 1.5 billion in 2024, impacting adjusted reimbursement models within pilot states. Medicare coverage expanded by 15.7% to USD 800.7 million, focusing especially on older citizens and PTSD patients. The market is still concentrated in Oregon, Colorado, and California, but nationwide expansion is anticipated by 2030 through federal policy normalization, further boosting clinical demand and commercial viability for suppliers.

North America Government Investment and Budget in Psilocybin-Assisted Therapy (2021-2025)

Asia Pacific Market Insights

APAC is the fastest-growing region in the psilocybin assisted therapy market and is anticipated to hold the market share of 17.6% at a CAGR of 18.2% in 2034. The market is accelerated by the progressive policy shifts, rising mental health prevalence, and investments in psychedelic-assisted treatments. India, China, and Japan together hold the maximum share in the Asia Pacific region. Japan’s openness in regulatory and integration in clinical practices has aided in institutionalizing psilocybin therapy, whereas with the large patient pool, China has catalyzed domestic manufacturing of psilocybin APIs. The region is shaped by rising acceptance among clinical researchers, unmet mental health needs, and increased funding from ministries of health. This makes the region favorable for manufacturers to provide therapy services in the upcoming years.

Japan leads the psilocybin assisted therapy market in the Asia Pacific region and is expected to have a market share of 6.2% in 2034. Japan has allocated 12.5% of the national healthcare budget to innovations in mental health diseases, including psilocybin-assisted therapies. As per the Ministry of Health, Labour and Welfare report, this budgeting has resulted in a USD 3.3 billion rise since 2022 due to the strategic focus on psychiatric conditions’ alternative treatments. Further, the Japan Agency for Medical Research and Development has aided 16 active psilocybin clinical trials aiming towards treatment-resistant depression (TRD) and palliative care.

APAC Psilocybin Assisted Therapy Market: Government Investment and Funding (2021-2025)

Europe Market Insights

The psilocybin assisted therapy market in Europe is growing rapidly and is projected to hold a market share of 29.7% at a CAGR of 15.6% in 2034. The market is driven by rising mental health prevalence, regulatory leniency, and strategic national health policies. The European Medicines Agency (EMA) has been actively facilitating psilocybin clinical trials through fast-track review and partnerships in pharmacovigilance. Public-private research collaborations and hospital-based network trials are also incorporated in the region. Increased patient demand for off-label psychiatric therapies, as well as expanding clinical data, is framing the market landscape in Europe and making it extremely favorable for treatment providers and manufacturers.

Germany holds the maximum share in the psilocybin assisted therapy market in Europe and is expected to maintain the market share of 7.7% in 2034. As per the Federal Ministry of Health, Germany's expenditure on psilocybin therapy has reached €4.5 billion in 2024, reflecting a 12.5% rise in national demand since 2021. The integration of mental treatment programs with wider access was promoted by the German Medical Association (BÄK). Further, Germany has more than 23 registered trials, including for addiction disorders and palliative care. Germany's early investment and coordinated trial network position it as a European growth leader.